| SC 13G | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | CytomX Therapeutics, Inc. | 2,677,658 | 6.0% | EDGAR |
| SC 13G/A | 2019-02-04 | BlackRock Inc. | CytomX Therapeutics, Inc. | 3,860,928 | 8.6% | EDGAR |
| SC 13G/A | 2018-02-14 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 544,918 | 1.4% | EDGAR |
| SC 13G/A | 2018-02-14 | PERCEPTIVE ADVISORS LLC | CytomX Therapeutics, Inc. | 2,490,381 | 6.5% | EDGAR |
| SC 13G/A | 2018-02-13 | PFIZER INC | CytomX Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | CytomX Therapeutics, Inc. | 5,761,294 | 15.0% | EDGAR |
| SC 13G/A | 2018-02-13 | THIRD ROCK VENTURES LP | CytomX Therapeutics, Inc. | 3,320,348 | 8.6% | EDGAR |
| SC 13G | 2018-02-01 | BlackRock Inc. | CytomX Therapeutics, Inc. | 2,646,599 | 6.9% | EDGAR |
| SC 13G | 2017-12-18 | PERCEPTIVE ADVISORS LLC | CytomX Therapeutics, Inc. | 2,165,381 | 5.6% | EDGAR |
| SC 13G/A | 2017-07-07 | Canaan IX L.P. | CytomX Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2017-06-30 | BIOTECHNOLOGY VALUE FUND L P | CytomX Therapeutics, Inc. | 941,783 | 2.6% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | CytomX Therapeutics, Inc. | 5,460,352 | 15.0% | EDGAR |
| SC 13G/A | 2017-02-13 | THIRD ROCK VENTURES LP | CytomX Therapeutics, Inc. | 7,670,348 | 21.1% | EDGAR |
| SC 13G/A | 2017-01-26 | Canaan IX L.P. | CytomX Therapeutics, Inc. | 3,244,381 | 8.9% | EDGAR |
| SC 13G/A | 2016-02-12 | FMR LLC | CytomX Therapeutics, Inc. | 5,403,643 | 15.0% | EDGAR |
| SC 13G | 2016-02-11 | Canaan IX L.P. | CytomX Therapeutics, Inc. | 4,884,755 | 13.6% | EDGAR |
| SC 13G | 2016-02-10 | THIRD ROCK VENTURES LP | CytomX Therapeutics, Inc. | 8,670,348 | 24.1% | EDGAR |
| SC 13G | 2015-11-10 | FMR LLC | CytomX Therapeutics, Inc. | 5,231,677 | 15.0% | EDGAR |
| SC 13G | 2015-10-21 | PFIZER INC | CytomX Therapeutics, Inc. | 2,017,604 | 5.6% | EDGAR |
| SC 13G | 2015-10-14 | Flynn James E | CytomX Therapeutics, Inc. | 275,000 | 0.8% | EDGAR |